Cempra To Present Full Data Set Of Phase 2 Clinical Trial Of CEM-101

Trade CEMP now with

3/31/2012 1:33 AM ET

Cempra Inc. (CEMP: Quote) said that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases or ECCMID, in London, demonstrating CEM-101's efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections or CABP.

The phase 2 clinical trial of the study also showcases olithromycin's favorable safety and tolerability profile compared to levofloxacin, the company added.

Solithromycin is the first fluoroketolide with a number of attributes that may provide clinically important advantages over several comparator products.

Prabhavathi Fernandes, chief executive officer of Cempra commented "This is the first time that the full data set of this Phase 2 trial has been available for review by the infectious disease community. The promising results of this clinical trial will now be the basis for the initiation of our Phase 3 program in CABP. We expect to begin the first Phase 3 trial evaluating oral solithromycin in moderate-to-moderately severe CABP patients in the second half of 2012."

The CEO stated " Additionally, we are planning Phase 3 trials for 2013 testing the efficacy of intravenous-to-oral step down administration of solithromycin in moderate-to-severe CABP."

In a separate press release, the clinical-stage pharmaceutical company noted that data will be presented at the ECCMID demonstrating that CEM-101 (solithromycin) would be active against antibiotic-resistant strains of N. gonorrhoeae.

Magnus Unemo, associate professor, National Reference Laboratory for Pathogenic Neisseria said "In vitro studies, including the presentation at ECCMID, have indicated that solithromycin can be a promising agent for treating patients with gonococcal infections. N. gonorrhoeae is becoming a serious public health problem because current antibiotic options are gradually becoming less effective in treating the disease. New options are required and solithromycin appears to be a promising candidate."

To receive FREE breaking news email alerts for Cempra, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 164 Articles

Editors Pick

Fed Concerns Contribute To Lackluster Session On Wall Street - U.S. Commentary

There was a mixed performance on Wall Street on Friday. Shares suffered an early decline, as investors continued to express worries about the Federal Reserve. A recovery through the rest of the day allowed the Dow to edge into positive territory by the close. The Nasdaq and S&P 500 posted fractional losses.

Stocks Come Under Pressure Amid Worries About The Fed - U.S. Commentary

Stocks have shown a notable move to the downside in early trading on Friday amid lingering concerns about the outlook for the Federal Reserve's asset purchase program. The major averages have slid firmly into negative territory, adding to the modest losses posted in the previous session. The major averages are currently posting notable losses, near their lows for the young session.

U.S. Durable Goods Orders Rise 3.3% In April, More Than Expected

After reporting a sharp drop in new orders for manufactured durable goods in the previous month, the Commerce Department released a report on Friday showing that durable goods orders rebounded by more than anticipated in the month of April. The report said durable goods orders surged up by 3.3 percent in April after tumbling by a revised 5.9 percent in March.